North Star Asset Management Inc. Purchases 2,194 Shares of Stryker Corporation $SYK

by · The Cerbat Gem

North Star Asset Management Inc. increased its position in Stryker Corporation (NYSE:SYK – Free Report) by 2.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 101,686 shares of the medical technology company’s stock after buying an additional 2,194 shares during the period. Stryker comprises approximately 1.4% of North Star Asset Management Inc.’s holdings, making the stock its 16th largest position. North Star Asset Management Inc.’s holdings in Stryker were worth $35,740,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SYK. United Financial Planning Group LLC bought a new position in shares of Stryker during the 3rd quarter valued at about $27,000. CGC Financial Services LLC bought a new position in shares of Stryker during the 4th quarter valued at about $29,000. Strive Asset Management LLC bought a new position in shares of Stryker during the 3rd quarter valued at about $30,000. ANTIPODES PARTNERS Ltd bought a new position in shares of Stryker during the 3rd quarter valued at about $34,000. Finally, Copia Wealth Management boosted its holdings in shares of Stryker by 181.6% during the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK opened at $316.39 on Friday. The firm has a market cap of $121.29 billion, a PE ratio of 36.62, a price-to-earnings-growth ratio of 1.99 and a beta of 0.80. The firm’s 50 day simple moving average is $325.22 and its 200-day simple moving average is $349.82. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the business posted $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analysts Set New Price Targets

Several research analysts have commented on SYK shares. UBS Group dropped their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Canaccord Genuity Group dropped their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a report on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 4th. Finally, Citigroup lowered their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $395.48.

Check Out Our Latest Stock Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Stories